Amarin Corp Plcuk (AMRN) Shares Outstanding (Weighted Average) (2010 - 2026)
Amarin Corp Plcuk (AMRN) reported Shares Outstanding (Weighted Average) of $419.1 million for Q1 2026, up 1.36% year-over-year from $413.4 million in Q1 2025, and up 0.98% quarter-over-quarter from $415.0 million in Q4 2025.
Amarin Corp Plcuk (AMRN) Shares Outstanding (Weighted Average) (2010 - 2026) Analysis & Trends
Amarin Corp Plcuk (AMRN) has 17 years of Shares Outstanding (Weighted Average) data on file, last reported at $419.1 million in Q1 2026.
- Shares Outstanding (Weighted Average) for Q1 2026 came in at $419.1 million, up 1.36% year-over-year; the trailing twelve-month figure through Mar 2026 was $419.1 million (up 1.36% YoY), and the FY2025 annual result was $415.0 million, up 0.98% from the prior year.
- Shares Outstanding (Weighted Average) advanced to $419.1 million in Q1 2026 per AMRN's latest filing, from $415.0 million in the prior quarter.
- Over five years, Shares Outstanding (Weighted Average) peaked at $419.1 million in Q1 2026 and troughed at $397.8 million in Q1 2022.
- A 5-year average of $408.9 million and a median of $410.1 million in 2024 frame the typical range for Shares Outstanding (Weighted Average).
- The sharpest annual moves came in 2023 and 2024: Shares Outstanding (Weighted Average) advanced 2.27% in 2023, then grew 0.67% in 2024.
- A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $401.2 million in 2022, then climbed by 1.62% to $407.7 million in 2023, then grew by 0.81% to $410.9 million in 2024, then advanced by 0.98% to $415.0 million in 2025, then grew by 0.98% to $419.1 million in 2026.
- Business Quant data shows AMRN's Shares Outstanding (Weighted Average) at $419.1 million in Q1 2026, $415.0 million in Q4 2025, and $415.5 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Weighted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | 1,818,692.66 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 894.50 Mn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 2.41 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 1.77 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | 2.47 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 540.00 Mn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 1.24 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 5.69 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 2.04 Bn |
| 10 | Amarin Corp Plcuk | 5.84 Bn | 5.66 Bn | 17.77 Mn | 419.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 419.05 Mn |
| Dec 31, 2025 | 414.98 Mn |
| Sep 30, 2025 | 415.53 Mn |
| Jun 30, 2025 | 414.48 Mn |
| Mar 31, 2025 | 413.42 Mn |
| Dec 31, 2024 | 410.94 Mn |
| Sep 30, 2024 | 411.15 Mn |
| Jun 30, 2024 | 410.57 Mn |
| Mar 31, 2024 | 410.15 Mn |
| Dec 31, 2023 | 407.66 Mn |
| Sep 30, 2023 | 408.42 Mn |
| Jun 30, 2023 | 407.02 Mn |
| Mar 31, 2023 | 406.18 Mn |
| Dec 31, 2022 | 401.16 Mn |
| Sep 30, 2022 | 404.61 Mn |
| Jun 30, 2022 | 398.00 Mn |
| Mar 31, 2022 | 397.81 Mn |
| Dec 31, 2021 | 395.99 Mn |
| Sep 30, 2021 | 396.62 Mn |
| Jun 30, 2021 | 395.27 Mn |